Lineage Cell Therapeutics, Inc. announced that results from imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation, "Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: Results from the Phase 1/2a trial" was presented by Eyal Banin, M.D., Ph.D., Director, Center for Retinal and Macular Degenerations, Department of Ophthalmology at Hadassah-Hebrew University Medical Center, on behalf of Roche and Genentech, a member of the Roche Group. RG6501 (OpRegan) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

It is being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech, and is currently being evaluated in a Phase 2a clinical study in patients with GA secondary to AMD. Overall, these data suggest that OpRegen RPE cells may provide support to the remaining retinal cells within atrophic areas by counteracting host RPE cell dysfunction and loss. Further assessment of the optimal disease stage for intervention and target delivery location of OpRegen in a larger clinical study is needed to confirm these preliminary findings.

A Phase 2a study evaluating the success of OpRegen delivery to target areas of GA is currently enrolling patients. Dr. Banin's presentation is now available on the Events and Presentations section of Lineage's website. The Association for Research in Vision and Ophthalmology, Inc. (ARVO) was founded in 1928 in Washington, DC by a group of 73 ophthalmologists.

ARVO is the largest and most respected eye and vision research organization in the world. ARVO members include nearly 11,000 researchers from over 75 countries. Lineage cautions that all state.